In accordance, mice vaccinated with DEVs from the poly(I:C) group had less tumor growth and longer survival in an in vivo B16-F10 tumor model, correlating with more robust activation of tumor-specific CD8+ T cells and recruitment NK and NKT cells [142]. Here, CD8A is linked to neoplasm.